Trinity Biotech plc - American Depositary Shares (TRIB)
0.9100
-0.0200 (-2.15%)
Trinity Bio is a biotechnology company focused on developing innovative therapies and diagnostics for various medical conditions
The company leverages advanced technologies to create solutions aimed at enhancing patient care and improving health outcomes. By prioritizing research and development, Trinity Bio strives to bring cutting-edge products to market that address unmet medical needs, while also engaging in partnerships and collaborations within the healthcare sector to expand its reach and efficacy in the industry.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its continuous glucose monitoring system.
Trinity Biotech stock surges on high volume after announcing increased orders for TrinScreen HIV, boosting 2024 revenue projections to $10 million. Second-quarter earnings show a 14% YoY revenue increase driven by strong HIV test sales.
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
